LADENBURG THALM/SH SH Raises TG Therapeutics (NASDAQ:TGTX) Price Target to $40.00

TG Therapeutics (NASDAQ:TGTX) had its price target increased by LADENBURG THALM/SH SH from $39.00 to $40.00 in a research report sent to investors on Thursday, Benzinga reports. LADENBURG THALM/SH SH currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on TGTX. B. Riley lifted their target price on TG Therapeutics from $24.00 to $29.00 and gave the company a buy rating in a research note on Monday, February 5th. JPMorgan Chase & Co. reiterated an overweight rating and issued a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday, April 18th. StockNews.com downgraded shares of TG Therapeutics from a buy rating to a hold rating in a research report on Saturday, February 24th. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a research note on Thursday, February 29th. Finally, HC Wainwright reissued a buy rating and set a $45.00 price target on shares of TG Therapeutics in a research note on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $29.83.

TG Therapeutics Stock Down 1.4 %

Shares of NASDAQ TGTX opened at $16.19 on Thursday. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The company has a market cap of $2.50 billion, a price-to-earnings ratio of 70.39 and a beta of 2.33. TG Therapeutics has a 12-month low of $6.46 and a 12-month high of $35.67. The firm’s 50-day simple moving average is $15.25 and its 200 day simple moving average is $14.46.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. The company had revenue of $63.47 million for the quarter, compared to analyst estimates of $54.60 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. TG Therapeutics’s revenue for the quarter was up 713.5% on a year-over-year basis. On average, research analysts expect that TG Therapeutics will post -0.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Laurence N. Charney sold 22,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the sale, the director now directly owns 215,229 shares of the company’s stock, valued at approximately $3,437,207.13. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Pingora Partners LLC acquired a new stake in TG Therapeutics during the 4th quarter worth $27,000. PNC Financial Services Group Inc. lifted its holdings in shares of TG Therapeutics by 131.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,014 shares in the last quarter. Anchor Investment Management LLC acquired a new position in shares of TG Therapeutics in the 4th quarter valued at approximately $80,000. NBC Securities Inc. bought a new stake in TG Therapeutics during the 3rd quarter worth approximately $58,000. Finally, REDW Wealth LLC acquired a new stake in TG Therapeutics during the 3rd quarter worth approximately $84,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.